Benign reversible encephalopathy syndrome after bevacizumab therapy for metastatic ovarian cancer
- 225 Downloads
Posterior reversible encephalopathy syndrome (PRES) is now a well-described entity in neurology, diagnosed by the clinical picture of altered mental status, headache, visual disturbances, hypertension and seizures, associated with the classical MRI findings of cortical and subcortical abnormalities in multiple brain areas, predominantly in the posterior lobes.
This entity has been associated with eclampsia, hypertensive encephalopathy, neurotoxic drugs, immunosuppressants and electrolyte disturbances .
We describe a case of PRES, following bevacizumab therapy in a patient with metastatic ovarian carcinoma. We are presenting this case to highlight the benign nature of the seizure component of this syndrome and to suggest modifying its nomenclature to benign reversible encephalopathy syndrome (BRES) because most of the reported cases in the literature describe lesion in the frontal and temporal lobes and not only the posterior lobes and the prognosis for recovery from this condition...
KeywordsBevacizumab Eclampsia Posterior Reversible Encephalopathy Syndrome Altered Mental Status Posterior Lobe
Conflict of interest
All authors declare that they have no conflict of interest.